Supplementary Figures 1-12 from HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma

Supplemental Figure 1: Gene ontology network analysis of uveal melanoma cells following MEKi treatment (24h) and ABPP. Supplemental Figure 2: ET-3 increases nuclear accumulation of YAP in 92.1, Mel270, MP41 and OMM1 cells. Supplemental Figure 3: ET-1 does not induce YAP reporter activity in 92.1 or Mel270 cells. Supplemental Figure 4: HDAC inhibitors increase the cytotoxic effects of MEK inhibition. Supplemental Figure 5: MEK inhibition leads to an increase in global protein acetylation in uveal melanoma cells. Supplemental Figure 6: MEKi, HDACi and the MEKi-HDACi combination do not affect the survival of primary uveal melanocytes. Supplemental Figure 7: HDACi suppresses MEKi-induced release of ET-3 from uveal melanoma cells. Supplemental Figure 8: Negative modulation of PI3K-AKT pathway by combinatory treatment with MEKi+HDACi. Supplemental Figure 9: The MEK-HDACi combination delivers durable responses in the 92.1 uveal melanoma xenograft model. Supplemental Figure 10: Macroscopic findings of liver tumor formation after inoculation of MP41 by tail vein injection. Supplemental Figure 11: Uncropped blots Supplemental Figure 12: Flow cytometry plots